In view of the therapeutic importance of 1,2,3-triazoles and the versatility of the copper-catalyzed Huisgen 1,3-dipolar cycloaddition (CuAAC), the present work proposes the synthesis of new compounds containing 1,2,3-triazoles-1,4-disubstituted derivatives by addressing the concept of molecular hybridization to obtain various triazole-containing compounds associated with other privileged pharmacophoric groups. The compounds synthesized were divided into two series and evaluated for their anticancer potential, as antileishmanial and central nervous system disorders. In order to the first series of triazoles, aryl azides were prepared from commercial anilines and propargylic ethers were obtained from commercial phenols. The key step of the CuAAC reaction afforded of 1,2,3-triazoles-1,4-disubstituted 50 - 85 percent in yields. All compounds were evaluated in different glioblastoma cell lines (GBM), including highly resistant human cell lines such as GBM02, GBM95, in which compounds 2,2-(4,4-((1,3 henylenebis(oxy))bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))dibenzaldehyde and (E)-4-methyl-N-(2-(4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl)benzylidene)benzenesulfonohydrazide were the most active, with IC50 of 28.7 and 30.3 uM, respectively. The triazole derivatives were also evaluated for the lung and prostate cancer strains (A549, 22Rv1), however, the compounds analyzed did not show activity in these cell lines. For the synthesis of the second series of hybrid compounds such as a-hydroxy-1,2,3-triazoles and benzochromenes-triazoles, aryl azides were prepared from aryl boronic acids and the propargylic alcohols from commercial benzaldehydes. The CuAAC reaction in the presence of sodium methoxide provided the novel a-hydroxy-1,2,3-triazoles in 35 and 75 percents yields. The a-hydroxy-1,2,3-triazoles, were aplied palladium-catalyzed intermolecular (C-O) cyclization reaction and provided benzocromenes-triazoles in 35-40 percent yields. These compounds were evaluated as inhibitors of glycine transporter (Gly T1), which are related to neurological disorders. Therefore, compound (2-bromophenyl) (1-(4-bromophenyl)-1H-1,2,3-triazol-4-yl)methanol showed the best result with 42 percent of inhibition and IC50 of 13 uM. All compounds were avaluated for antileishmanial activity (L. amazonenses), compounds 2,2-(4,4-((1,3-phenylenebis(oxy))bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))dibenzaldehyde and (E)-4-methyl-N-(2-(4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl)benzylidene)benzenesulfonohydrazide presented the best results, with IC50 de 8,85 e 8,81 uM, respectively. All the compounds synthesized were characterized by nuclear magnetic resonance (NMR), infrared (FTIR) spectroscopy and mass spectrometry (GC-MS) techniques.